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INTRODUCTION
In vivo  adm inistration of Gram-negative bacteria or endotoxin 
(Iipopolysaccharide, LPS) induces a transient refractoriness to a subsequent challenge by 
LPS. Manifestations such as fever, hypoglycemia, hypotension, shock and death are 
decreased or avoided for a period of 3-4 days following an initial injection with non-lethal 
doses of LPS (He et al., 1992). This observation could reflect an endotoxin tolerance. 
Endotoxin tolerance is mainly a macrophage-mediated phenomenon (Freudenberg and 
Galanos, 1988). We and others have previously shown that monocytes isolated from 
patients with sepsis syndrome had a reduced ability to produce IL -la, IL-lp, IL-6 and 
TNFa upon in vitro stimulation (Luger et al., 1986; Helminen, 1991; Munoz et al. 
1991, Simpson et al., 1991). Van Deuren et al. (1994), studying patients with acute 
meningococcal infections, have confirmed this observation using a whole blood assays. In 
addition, they reported that the ex vivo IL-lra production, after LPS stimulation, was 
enhanced or maintained but never reduced as it was observed for the inflammatory 
cytokines. The authors suggested that the down-regulation of inflammatory cytokines 
production and up-regulation of IL-lra production during acute infection could serve as a 
mechanism of protection.
In an in vitro model of LPS-tolerance using human monocytes from healthy 
donors (Matic and Simon, 1991; Cavaillon et al. 1994), we have investigated whether 
such different regulation exists between TNFa and IL-lra.
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METHODS AND RESULTS
Human monocytes selected by adherence were incubated for 22 h in culture 
medium supplemented with 0.2% normal human serum and 1 fig/ml indomethacin, alone 
or in the presence of 2 fig/ml Neisseria meningitidis (N.m.) LPS. The cells were then 
washed extensively, and cultured for different period of times in the same culture medium, 
in the absence or the presence of 2 jxg/ml N.m. LPS. TNFa and IL-lra were assessed at 
transcriptional level using Northern blot analysis and at protein level using specific 
ELISAs. As shown in figure la, 1 h of restimulation with LPS was unable to induce 
significant amounts of TNFa mRNA in LPS-tolerized human monocytes while 
transcription of the TNFa gene occurred in non LPS-pretreated cells. Absence, or weak 
expression of TNFa mRNA was similarly observed after both 1 h or 4 h of LPS 
restimulation in the tolerized monocytes. It is worth noting that, while TNFa mRNA 
expression is maximum after lh in freshly isolated monocytes (Wollenberg et al. 1993), 
in untreated pre-culture monocytes expression of TNFa mRNA was greater 4 h after 
stimulation with LPS than after 1 h of stimulation.
In contrast, 1 h after restimulation with LPS, transcription of IL-lra in LPS- 
tolerized human monocytes was enhanced in comparison with untreated precultured mono-
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F igu re  1: TNFa mRNA/p-actin mRNA ratio (a) and IL-lra mRNA/p-actin mRNA ratio 
(b) in human monocytes cultured in the absence or the presence of N.m. LPS (2 ¿ig/ml) 
for 22 h, and monocytes were challenged or not in the presence of N.m. LPS (2 p,g/ml) 
for different time. Relative densities were obtained by scanning the northern blots by laser 
densitometer.
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cytes (figure lb). Even after 18 h of LPS restimulation, IL-lra mRNA expression 
remained high in the to le rized  monocytes.
We also assessed TNFa and IL-lra release in LPS-tolerized and untreated 
precultured monocytes supematants. One hour after LPS restimulation, TNFa release in 
LPS-tolerized monocytes was close to that measured in untreated precultured monocytes 
(TNFa release = 327 ± 77 pg/ml vj 309 ± 92 pg/ml by LPS-tolerized monocytes vs 
untreated precultured monocytes; n = 5). These results did not reflect those obtained at 
transcriptional level. A further incubation (4 h) of LPS-tolerized human monocytes with 
LPS led to a low TNFa release (Table 1) as compared to untreated pre-cultured cells. This 
last result correlates with those obtained at the transcriptional level.
One hour after LPS restimulation, IL-lra release in LPS-tolerized monocytes was 
sometimes enhanced or identical to IL-lra release measured in untreated precultured 
monocytes (IL-lra release = 1361 ±319  pg/ml vs 1227 ±314  pg/ml by LPS-tolerized 
monocytes vs untreated precultured monocytes; n = 5). Moreover, the enhancement 
observed sometimes at protein release level was not identical to that observed at 
transcriptional level. IL-lra released by LPS-tolerized monocytes and restimulated 4 h 
with LPS was slightly decreased (10%) as compared to untreated precultured monocytes 
(Table 1). This result did fully reflect what was observed at transcriptional level, since IL- 
lra  mRNA expression was higher than that obtained with untreated precultured monocytes 
(figure lb). Twenty-six hours-culture supematants of control human monocytes (untreated 
precultured and unchallenged monocytes) were not able to release TNFa (30 pg/ml) but 
spontaneous IL-lra was measured in supematants (3475 pg/ml).
As previously described (Cavaillon et al., 1994), 18-24h after restimulation with 
LPS of LPS-tolerized human monocytes, a more complete inhibition of TNFa release 
(94%) was observed (figure 2), whereas only a weak decrease of IL-lra protein release 
(34%) was noticed (figure 2).
Table 1: TNFa and IL-lra release upon N.m . LPS (2 jig/ml) activation by untreated 
precultured and LPS-tolerized human monocytes (22 - 26 h). This experiment was 
representative of five.
pretreatment Challenge Cytokines recovered (T= 26h)
(T = 0 - 22 h) (T = 22 -26h) TNFa (pg/ml) IL-lra (pg/ml)
none none 30 3475
none LPS 46,430 10,494
LPS LPS 8,676 9,479
(-81%) (-10%)
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Figure  2: TNFa and IL-lra release upon N.m. LPS (2 |ig/ml) activation by untreated 
precultured and LPS-tolerized human monocytes (22 - 40 h). Each line represent an 
individual donor (n = 6)
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We have compared the in vitro synthesis of TNFa and IL-lra in monocytes of 
healthy donors, using a LPS-tolerance model. It appears that TNFa and IL-lra were 
differently regulated in LPS-tolerized monocytes model. These data are in agreement with 
ex vivo results reported by Van Deuren et al. (1994) during meningococcal infection.
We have previously showed that TNRx was completely down-regulated, when LPS- 
tolerized-monocytes were challenged with LPS (Cavaillon et al., 1994). In the present 
work, we demonstrate that one hour of restimulation with LPS leads to a significant 
reduction of TNFa translation, whereas whithin Ih no down-regulation was observed at 
protein release level. Four hours after LPS restimulation of LPS-tolerized monocytes, 
both transcriptional and protein level were down-regulated as compared to untreated 
precultured monocytes. Interestingly, we observed a shift in the kinetic of TNFa mRNA 
expression. TNFa mRNA was better expressed 4 h after LPS stimulation than after 1 h 
in untreated precultured monocytes whereas it is the opposite observation in freshly 
isolated human monocytes. Another difference between translation and protein release was 
found with IL-lra. We showed that 1 and 4 h after LPS restimulation, IL-lra mRNA was
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enhanced in LPS-tolerized monocytes as compared to untreated precultured cells. This 
enhancement was not associated with an increase of protein release. In LPS-tolerized 
monocytes restimulated 18 h with LPS, a weak low protein release was observed as 
compared to untreated precultured monocytes, whereas TNFa protein release was totally 
inhibited in LPS-tolerized cells. At this time, no TNFa mRNA expression was observed 
in both LPS-tolerized and untreated precultured monocytes. Another set of experiments to 
evaluate cell-associated IL-lra protein is required in an attempt to further analyse the 
discrepancy between the observed enhanced IL-lra mRNA expression and the absence of 
increased release of IL-lra.
We have previously shown that IL-1, IL-10 and TGFp could render human 
monocytes hyporeactive to further activation by LPS, leading to a reduced TNF 
(Cavaillon et al., 1994). IL-10 and TGFp are produced by monocytes after LPS 
stimulation and it is well established that these 2 cytokines can enhance IL-lra synthesis 
in LPS-stimulated monocytes (Wahl et al., 1993; de Waal Malefyt et al., 1993; Jenkins et 
al., 1994). Moreover, IL-1 produced after LPS stimulation could also induce IL-lra 
synthesis (Wahl et al., 1993). We could hypothesize that IL-lra enhancement seen in 
LPS-tolerized monocytes was the consequence of the synthesis of these cytokines.
In vivOy additional mechanism could be involved. IL-4 might play a role in this 
process. Wong et al. showed that after IL-4 therapy, monocytes from cancer patients 
expressed a marked increase in IL-lra mRNA, which was reflected by significant increase 
in serum level (Wong et al., 1993). Furthemore, IL-4 down-regulates the LPS-stimulated 
pro-inflammatory cytokines production by human PBMC and monocytes, whereas IL-4 
increases the synthesis of IL-lra by these cells (Te Velde et al., 1990; Vannier et al., 
1992; de Waal et al., 1993). Further studies on the regulatory mechanism of TNFa and 
IL-lra synthesis in LPS-tolerant human monocytes could help us for the comprehension 
of the complex cytokines network involved in tolerance phenomenon.
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